TYRA — Tyra Biosciences, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1863127 ·
Last close
$21.76
Market Cap
$1.30B
52W High
$40.65
52W Low
$12.58
ADV30
1,058,700
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -49,003,000 | -45,558,000 | 383,362,000 | 73,835,000 | 29,698,000 |
| Mar 2026 | 0 | — | -41,998,000 | -39,305,000 | 412,040,000 | 84,955,000 | 24,465,000 |
| Dec 2025 | 0 | — | -36,516,000 | -33,834,000 | 282,609,000 | 77,387,000 | 23,432,000 |
| Sep 2025 | 0 | — | -32,944,000 | -29,868,000 | 301,851,000 | 61,951,000 | 21,342,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-109,651,000
Investing CF
$-82,819,000
Financing CF
$167,815,000
CapEx
$-250,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-2.40
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-456,121,000
Inventory
—
Receivables
—
ST Investments
$280,109,000
EBIT TTM
$-160,461,000
Pretax Income TTM
$-148,565,000
Interest Exp TTM
—
Analysts
12
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -132,762,000 | -119,947,000 | 282,609,000 | 23,432,000 | 259,177,000 | -95,142,000 |
| Dec 2024 | 0 | -104,177,000 | -86,481,000 | 363,558,000 | 20,407,000 | 343,151,000 | -69,774,000 |
| Dec 2023 | 0 | -79,945,000 | -69,134,000 | 225,857,000 | 21,595,000 | 204,262,000 | -50,139,000 |
| Dec 2022 | 0 | -58,927,000 | -55,325,000 | 266,181,000 | 8,352,000 | 257,829,000 | -50,285,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.88
Max Pain — expiry 2026-10-16
max pain strike: $22.50 · spot: $21.28 · call oi: 151 · put oi: 3,865
Expected Move to 2026-10-16:
±$5.97
(28.08%) —
implied range
$15.31 –
$27.26
· ATM straddle on $22.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DMRA | Damora Therapeutics, Inc. | $1.28B | $20.66 | — |
| BCAX | Bicara Therapeutics Inc. | $1.27B | $19.21 | — |
| AVLN | Avalyn Pharma Inc. | $1.24B | $28.08 | — |
| HROW | HARROW, INC. | $1.24B | $33.07 | — |
| ORIC | Oric Pharmaceuticals, Inc. | $1.36B | $13.16 | — |
News headlines (Yahoo Finance, 1h cache)
Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
2026-09-14 10:45 · Yahoo
Tyra Plummets To 10-Month Low On Mixed Cancer Test; Why Analysts Are Upbeat
2026-09-09 20:54 · Yahoo
Tyra disappoints investors with bladder cancer data
2026-09-09 15:46 · Yahoo
Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress
2026-09-09 14:44 · Yahoo
Tyra Biosciences shares plunge 30% after Phase 2 dabogratinib data
2026-09-09 14:05 · Yahoo
Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib
2026-09-09 11:00 · Yahoo
Tyra Biosciences to Present at the Cantor Global Healthcare Conference
2026-09-08 20:05 · Yahoo
TYRA Stock Heads For Best Day In Nearly 10 Months — Sets Date For Key Phase 2 Bladder Cancer Drug Readout
2026-09-04 18:25 · Yahoo
Is Tyra Biosciences (TYRA) Too Reliant On Dabogratinib Amid Renewed SURF-302 Skepticism?
2026-06-12 01:16 · Yahoo
Tyra Biosciences' Weak Investor Sentiment Reflects Macro Pressures, Renewed SURF-302 Concerns, BofA Says
2026-06-10 14:57 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.